Insider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Purchases 10,000 Shares of Stock

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory L. Weaver purchased 10,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was bought at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Altimmune Trading Up 6.2 %

NASDAQ:ALT traded up $0.32 during trading hours on Friday, hitting $5.52. 861,233 shares of the stock traded hands, compared to its average volume of 3,004,274. Altimmune, Inc. has a fifty-two week low of $5.14 and a fifty-two week high of $11.16. The firm has a market cap of $425.27 million, a price-to-earnings ratio of -3.56 and a beta of 0.87. The firm has a 50 day moving average price of $6.51 and a 200 day moving average price of $7.12.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Research analysts predict that Altimmune, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. William Blair assumed coverage on Altimmune in a research report on Friday, February 28th. They set a “market perform” rating for the company. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Monday, March 3rd. Finally, Stifel Nicolaus began coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Hedge Funds Weigh In On Altimmune

A number of institutional investors have recently made changes to their positions in the business. Ameriprise Financial Inc. increased its position in Altimmune by 35.6% in the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock worth $37,888,000 after buying an additional 1,378,854 shares during the period. Bellevue Group AG increased its stake in Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares during the period. Invesco Ltd. raised its holdings in Altimmune by 679.2% in the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company’s stock valued at $1,781,000 after acquiring an additional 215,375 shares in the last quarter. Millennium Management LLC increased its position in shares of Altimmune by 139.8% during the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company’s stock valued at $2,492,000 after purchasing an additional 201,484 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of Altimmune by 33.2% in the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock valued at $4,364,000 after purchasing an additional 151,001 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.